BioSpace News Archive

FDA

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex Corp. today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for NRC, the company’s product candidate for the treatment of Ataxia Telangiectasia (AT).

June 7, 2024
·
8 min read
BioMidwest

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

SeaStar Medical Holding Corporation announces the publication of a peer-reviewed article in NatureScientific Reports that describes the mechanism of action of the Company’s Selective Cytopheretic Device in the immunomodulation of excessive inflammation.

June 7, 2024
·
6 min read
Genetown

Combined General Meeting of June 24, 2024

Biophytis SA will hold its Combined General Meeting on June 24, 2024 at 2pm at Sorbonne Université - Amphi Herpin - 4 Place Jussieu, 75005 Paris.

June 7, 2024
·
3 min read
Business

Solarvest Elects New Board of Directors

Solarvest BioEnergy Inc. (TSXV: SVS.H) (“Solarvest”, or the “Company”), an algal biologic company specializing in organic ingredient production

June 7, 2024
·
4 min read
NervGen Pharma Grants Stock Options.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000

June 7, 2024
·
1 min read
Biotech Bay

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics, Inc. announced today that it will host a sponsored symposium to present the largest and most diverse set of data to date from a cohort of 50 patients treated with the CAR in KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy.

June 7, 2024
·
5 min read
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure

NeurAxis, Inc. today announced a submission to the FDA for expansion of its IB-Stim label. The new submission is significant as it would allow access to a larger patient population beyond 11-18 years of age and allow for marketing of 4 devices per prescription.

June 7, 2024
·
5 min read
Potential Add-on Treatment for Patients with Parkinson’s Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results

Stimvia, a pioneering medical technology company specializing in neuromodulation for chronic disease treatment, has successfully completed its pilot study focused on Parkinson’s Disease and is expecting promising results.

June 7, 2024
·
2 min read
Deals

Octane Medical acquires B. Braun’s global orthobiologics business

Octane Medical Group, through its new venture Octane Biotherapeutics (BioTx), has acquired 100% shares of the global

June 7, 2024
·
4 min read